CN115887265A

CN115887265A - JAK1 signal channel inhibitor and application thereof in anti-inflammatory and soothing cosmetics

Info

Publication number: CN115887265A
Application number: CN202211368442.2A
Authority: CN
Inventors: 韩新彬; 张阳; 王卫国; 蒋旭峰; 蓝艺珺; 徐文平
Original assignee: Frog Prince Fujian Baby Care Products Co ltd; East China University of Science and Technology
Current assignee: Frog Prince Fujian Baby Care Products Co ltd; East China University of Science and Technology
Priority date: 2022-11-03
Filing date: 2022-11-03
Publication date: 2023-04-04

Abstract

The invention belongs to the technical field of cosmetics, and provides a JAK1 signal pathway inhibitor and application thereof in anti-inflammatory and soothing cosmetics, wherein the JAK1 signal pathway inhibitor is selected from tetrandrine which is one or more of tetrandrine or fangchinoline. The tetrandrin has an inhibiting effect on a JAK1 signal path, and the expression of STAT6mRNA and related cytokine IL-4mRNA is reduced, so that the effect of relieving inflammatory response is achieved. The invention applies the tetrandrine to the preparation of the anti-inflammatory and soothing cosmetics, can enhance the inhibition effect of the products on JAK1 signal channels, and has the effect of enhancing the anti-inflammatory and pain-relieving effects of the cosmetics.

Description

JAK1 signal channel inhibitor and application thereof in anti-inflammatory and soothing cosmetics

Technical Field

The invention belongs to the technical field of cosmetics, and particularly relates to a JAK1 signal pathway inhibitor and application thereof in anti-inflammatory and soothing cosmetics.

Background

JAKs belong to the family of non-receptor protein tyrosine kinases, which have 4 proteins, JAK1, JAK2, JAK3 and TYK2, respectively. Among them, other than JAK3 is mainly expressed in hematopoietic cells, other members of the JAK family can be widely expressed in various cells and tissues. Activated Janu kinase (JAK 1) can function as a kinase and activate STAT proteins, causing the latter to form homo-or heterodimers that enter the nucleus where they bind to corresponding DNA elements, activating expression of downstream genes. However, in certain pathological conditions, the inflammatory process is considered to be a local protective response when the body is attacked or damaged by pathogens. JAK-STAT is a major signaling pathway regulated by cytokines and is critical for initiating innate immunity, coordinating adaptive immune mechanisms, and ultimately suppressing inflammation and immune responses. IL-4 is produced primarily by activated T cells in humans. The cytokine IL-4 may activate the JAK1/STAT6 signaling pathway by binding to the receptor.

Reactive Oxygen Species (ROS) are chemically reactive chemical species containing oxygen. Including peroxides, superoxides, hydroxyl radicals and singlet oxygen, and the like. In a biological context, ROS form a natural byproduct of the normal metabolism of oxygen and play an important role in cell signaling and homeostasis. However, ROS levels increase dramatically under stimuli such as foreign substances. This can cause severe damage to the cell structure, which is referred to as oxidative stress.

Phagocytosis of phagocytes is an important factor constituting nonspecific immunity of the body. Phagocytes are divided into large phagocytes, i.e., macrophages fixed in tissues and monocytes in the blood; and small phagocytic cells, i.e., neutrophils in the blood. They have the functions of phagocytosis, digestion and removal of foreign matters, and are one of the important mechanisms of the natural defense of the body. The check of phagocytic rate and index of phagocyte can reflect phagocytic function of phagocyte, and is also helpful for determining body's immune function.

The tetrandra plant as Chinese medicine material has the functions of relieving pain, diminishing inflammation, resisting allergy, etc. Tetrandrine including tetrandrine and tetrandrine can be extracted from the root. Hanfangchin A is a calcium ion antagonist and mainly influences transmembrane transport and distribution utilization of calcium ions in cells. In addition, tetrandrine also has effects of protecting liver cell, resisting hepatic fibrosis, reducing portal hypertension, preventing and treating portal hypertension, resisting tumor, and reversing drug resistance. At present, it has been confirmed to have a certain anti-inflammatory effect. The pharmacological action of hanfangchin B is similar to that of oridonin, and has antitumor, collagen-induced platelet aggregation inhibiting, analgesic and antiinflammatory effects. In the prior art, in the process of preparing anti-inflammatory and soothing cosmetics by using Chinese herbal medicines, a plurality of Chinese herbal medicine components are usually added for matching use, so that the preparation process of the cosmetics is relatively complicated, and the report that the tetrandrine is used as a JAK1 signal pathway inhibitor and is applied to the anti-inflammatory and soothing cosmetics is not found.

Disclosure of Invention

In view of the above problems, the present invention provides a JAK1 signaling pathway inhibitor and its use in anti-inflammatory soothing cosmetics.

In order to achieve the above purpose, the invention provides the following technical scheme:

the invention provides a JAK1 signal pathway inhibitor, wherein the JAK1 signal pathway inhibitor is selected from tetrandrine, and the tetrandrine is one or more of tetrandrine or fangchinoline.

Further, the JAK1 signaling pathway inhibitor is useful for inhibiting expression of JAK1, STAT6mRNA and the related cytokine IL-4 mRNA.

The invention discloses application of the JAK1 signal channel inhibitor in anti-inflammatory and soothing cosmetics.

Furthermore, the anti-inflammatory and soothing cosmetics comprise cosmetic raw products and tetrandrine, wherein the tetrandrine is one or more of tetrandrine or fangchinoline.

The anti-inflammatory and soothing cosmetic disclosed by the invention has the effect of enhancing inflammation and relieving after the tetrandrine is added into the original cosmetic.

Further, the purity of the tetrandrine and the tetrandrine is more than or equal to 95%.

Further, the weight percentage of the tetrandrine is 0.1-2%.

Further, the tetrandrine is composed of tetrandrine and fangchinoline, and the addition amount of the tetrandrine accounts for 40-100% of the total mass of the tetrandrine.

Preferably, the addition amount of the tetrandrine accounts for 50-100% of the total mass of the tetrandrine.

The invention also provides an anti-inflammatory soothing cosmetic comprising the JAK1 signaling pathway inhibitor.

Further, the preparation method of the anti-inflammatory and soothing cosmetic comprises the following steps: quantitatively weighing cosmetic raw materials, slowly heating, adding a certain amount of tetrandrine, and stirring to dissolve completely. Slowly heating, dissolving completely, standing, cooling, and storing when the temperature of the cosmetic reaches room temperature.

The present invention also provides a method for evaluating the anti-inflammatory activity of the JAK1 signaling pathway inhibitor in the anti-inflammatory soothing cosmetic, the method being selected from the group consisting of:

the method comprises the following steps: by establishing a HaCaT cell model, detecting the mRNA expression quantity of JAK1, STAT6 and IL-4 in a qPCR (quantitative polymerase chain reaction) mode, and evaluating the inhibition effect of the anti-inflammatory and soothing cosmetics on a JAK1 signal channel;

the method 2 comprises the following steps: by establishing a HaCaT cell model, detecting the ROS level by adopting a fluorescence photographing mode, and evaluating the capability of the anti-inflammatory and soothing cosmetics for relieving inflammatory reaction;

the method 3 comprises the following steps: establishing a THP-1 cell model, and detecting the phagocytosis capacity of neutral red blood by means of photomicrography and OD value so as to evaluate the capacity of the anti-inflammatory and soothing cosmetics for relieving inflammatory reaction; among the above 3 methods, method 1 or method 1 and method 2 or method 1 and method 3 or method 1 and method 2 and method 3.

Compared with the prior art, the invention has the following beneficial effects:

(1) The invention discloses a method for adding tetrandrin serving as a JAK1 signal channel inhibitor into anti-inflammatory and soothing cosmetics, and the tetrandrin can effectively inhibit the expression of JAK1, STAT6 and IL-4mRNA after LPS induction and slow down inflammatory reaction.

(2) The invention discloses a JAK1 signal channel inhibitor which can inhibit oxidative stress and cell phagocytosis reduction generated after LPS induction when added into anti-inflammatory and soothing cosmetics.

(3) In the invention, the tetrandrine is added into the anti-inflammatory and soothing cosmetics as the JAK1 signal pathway inhibitor, and when the addition amount of the tetrandrine is low, the pain relieving effect can be further optimized by adjusting the content ratio of the tetrandrine to the tetrandrine.

Drawings

FIG. 1 is a schematic representation of the effect of cosmetic treatment on JAK1 mRNA expression in HaCaT cells according to various examples.

FIG. 2 is a graphical representation of the effect of cosmetic treatment on STAT6mRNA expression in HaCaT cells in various examples.

FIG. 3 is a graphical representation of the effect of cosmetic treatments of various examples on IL-4mRNA expression in HaCaT cells.

FIG. 4 is a graphical representation of the effect of various example cosmetic treatments on the level of ROS in HaCaT cells.

FIG. 5 is a statistical plot of ROS levels in HaCaT cells quantified by cosmetic treatment in each example.

FIG. 6 is a graphical representation of the effect of cosmetic treatment on the phagocytic capacity of neutral red blood of THP-1 cells in various examples.

FIG. 7 is a statistical chart of the performance of the cosmetic treatment on the phagocytosis of neutrophilic erythromelans of THP-1 cells in each example.

Detailed Description

In order to more clearly illustrate the present invention, the present invention is further described below in conjunction with preferred embodiments. It is to be understood by persons skilled in the art that the following detailed description is illustrative and not restrictive, and is not to be taken as limiting the scope of the invention.

The molecular formula of tetrandrine used in the embodiment of the invention is C ₃₈ H ₄₂ N ₂ O ₆ The purity of alkaloid extracted from the roots of tetrandra root of the family Menispermaceae is more than 95%, and the specific structural formula is as follows:

the molecular formula of tetrandrine used in the embodiment of the invention is C ₃₇ H ₄₀ N ₂ O ₆ The purity of alkaloid extracted from the roots of tetrandra root of the family Menispermaceae is more than 95%, and the specific structural formula is as follows:

examples 1-8 preparation of anti-inflammatory soothing type cosmetic

The application of the tetrandrine as JAK1 signal pathway inhibitor in preparing anti-inflammatory and soothing cosmetics comprises the following steps:

firstly, selecting a prepared tea oil cosmetic raw product;

secondly, weighing 500g of tea oil for later use, slowly heating the tea oil to 30-50 ℃, adding tetrandrine with the formula amount shown in the table 1 into the tea oil, and continuously stirring the mixture to fully dissolve the tetrandrine; the addition amount of tetrandrine is shown in table 1;

and step three, slowly heating during the period, standing and cooling after complete dissolution. And storing the tea oil when the temperature of the tea oil reaches the room temperature for subsequent detection.

TABLE 1 anti-inflammatory soothing cosmetic formulations

Cosmetic composition	Tea oil/g	Tetrandrine/g	Tetrandrine/g
				Example 1	500	0.5	0
Example 2	500	10	0
				Example 3	500	0	0.5
Example 4	500	0	10
				Example 5	500	0.25	0.25
Example 6	500	0.2	0.3
				Example 7	500	0.3	0.2
Example 8	500	5	5

The anti-inflammatory, soothing type cosmetic prepared in each of the above examples was subjected to the following performance tests:

example 9 anti-inflammatory and soothing efficacy of JAK1 Signal pathway-based assay products

By establishing a HaCaT cell model and detecting the mRNA expression quantity of JAK1, STAT6 and IL-4 in a qPCR mode, the anti-inflammatory and soothing cosmetics added with the tetrandrin are evaluated, and the inhibition effect of the cosmetics on a JAK1 signal channel is achieved.

The specific process is as follows:

(1) Cell culture: haCaT cells (purchased from the Chinese cell resource pool) were selected. DMEM culture medium is selected, and 10% of serum and 1% of double antibody are added in the preparation of the culture medium. Selecting cell culture bottle for culturing, adding 5-6mL culture medium into each bottle, and subculturing once every 2-3 days. When the cells grow to 80% -90% of the bottom surface of the culture flask, 0.25% pancreatin is used for digestion, the cells are uniformly blown, and the cells are diluted to 10% ⁶ one/mL. Then, the cell suspension was transferred to a 60mm petri dish, 3mL of the cell suspension was added to each dish, mixed well, and then allowed to stand. After all cells settled, the cells were placed at 37 ℃ in 5% CO ₂ Culturing in an incubator for 24h, and adding medicine.

(2) The experimental group was set up: the total number of the samples was 11, which were blank control group, model group, control group, model + example 1 group, model + example 2 group, model + example 3 group, model + example 4 group, model + example 5 group, model + example 6 group, model + example 7 group and model + example 8 group. Wherein, the HaCaT cells of the blank control group grow normally, and other substances are not added into the culture medium in the dosing process; haCaT cells in the model group are induced by LPS, and other substances are not added into a culture medium in the dosing process; inducing HaCaT cells of the control group by LPS, and adding a tea oil raw product into a culture medium in the dosing process; model + HaCaT cells of group 1 were induced by LPS, and the medium was supplemented with the cosmetic of example 1 (10. Mu.g/mL) during the dosing; model + HaCaT cells of group 2 were induced by LPS, and during the dosing, the cosmetic of example 2 (10. Mu.g/mL) was added to the medium; model + HaCaT cells from group 3 were induced by LPS, and during the dosing, the medium was supplemented with the cosmetic of example 3 (10. Mu.g/mL). The HaCaT cells of the model + example 4 group were induced by LPS, the cosmetic of example 4 (10 μ g/mL) was added to the medium during the drug addition, the HaCaT cells of the model + example 5 group were induced by LPS, the cosmetic of example 5 (10 μ g/mL) was added to the medium during the drug addition, the HaCaT cells of the model + example 6 group were induced by LPS, the cosmetic of example 6 (10 μ g/mL) was added to the medium during the drug addition, the cosmetic of example 7 (10 μ g/mL) was added to the medium during the drug addition, the HaCaT cells of the model + example 8 group were induced by LPS, and the cosmetic of example 8 (10 μ g/mL) was added to the medium during the drug addition.

(3) RNA extraction: RNA extraction was performed by Trizol method. First, the petri dish dosed for 24h was removed, the medium was removed, and then washed twice with 4 ℃ pre-cooled PBS. Adding 1mL of Trizol into each dish, blowing down adherent cells, transferring into a 1.5mL centrifuge tube without enzyme, and standing for 3min. Adding 380 μ L chloroform, mixing by vortex, and standing for 3min. Using a refrigerated centrifuge, set program 4 ℃/12000rpm/15min, carefully transfer supernatant liquid after completion (ii)>500 μ L) into a new enzyme-free 1.5mL centrifuge tube. According to the volume of the transferred liquid, 1:1 is added with isopropanol, inverted and mixed evenly, and then placed in a refrigerator with the temperature of minus 20 ℃ for standing for 10 to 15min. Then, the mixture was centrifuged at 4 ℃/12000rpm/10min, and the supernatant was discarded. Adding 1mL 75% ethanol (prepared by DEPC), and washingThe precipitate was washed and centrifuged at 4 ℃/12000rpm/5min to remove the liquid as dry as possible. The precipitated RNA was air-dried, and after the RNA was slightly dried, 20. Mu.L of DEPC was added to dissolve the RNA. Finally, electrophoresis and OD ₂₆₀ /OD ₂₈₀ And (4) detecting and determining whether the RNA can be used for subsequent experiments.

(4) Reverse transcription: first strand cDNA synthesis was performed using a reverse transcription kit (purchased from Wuhan Severer). 20 μ L of reaction system, programmed as follows:

(5) qPCR detection: quantitative detection of mRNA was performed using the qPCR detection kit (purchased from Wuhanseweier) with the addition of primers. 20 μ L of reaction system, program set up as follows:

based on the obtained CT values, GAPDH was used as an internal reference, and 2 was used ^-ΔΔCT The method performs the calculation, and the calculation result is shown in fig. 1-3.

As shown in fig. 1, the expression level of JAK1 mRNA was significantly increased after LPS induction in the model group, whereas the expression level of JAK1 mRNA was significantly decreased when using the different examples compared to the model group, but still higher than the blank control group. Expression level of JAK1 mRNA: model group > control group > model + example 3 group > model + example 6 group > model + example 1 group > model + example 5 group > model + example 4 group > model + example 7 group > model + example 8 group > model + example 2 group > blank control group. As shown in fig. 2, the expression level of STAT6mRNA was significantly increased after LPS induction in the model group, whereas the expression level of STAT6mRNA was significantly decreased when using the different examples compared to the model group, but still higher than the control group. STAT6mRNA expression level: model group > control group > model + example 3 group > model + example 6 group > model + example 5 group > model + example 7 group > model + example 1 group > model + example 4 group > model + example 8 group > model + example 2 group > blank control group. As shown in FIG. 3, the expression level of IL-4mRNA was significantly increased after LPS induction in the model group, whereas the expression level of IL-4mRNA was significantly decreased when using the different examples, but still higher than that in the control group. Expression level of IL-4 mRNA: model group > control group > model + example 5 group > model + example 7 group > model + example 1 group > model + example 3 group > model + example 6 group > model + example 4 group > model + example 8 group > model + example 2 group > blank control group. Experiments prove that the anti-inflammatory and soothing cosmetics added with the tetrandrine can effectively inhibit the expression of JAK1, STAT6 and IL-4mRNA after LPS induction, have the anti-inflammatory and soothing effects, and have the inhibiting effect on a JAK1 signal channel by adding the tetrandrine which is superior to the tetrandrine. The tetrandrine and the tetrandrine are added in a mixing way, and the proportion of the tetrandrine to the tetrandrine is adjusted, so that the content of the tetrandrine is larger than that of the tetrandrine, and the excellent anti-inflammatory and soothing effects can be realized while the addition amount of the tetrandrine is lower.

Example 10ROS level detection

HaCaT cells (purchased from the Chinese cell resource Bank) were selected. DMEM medium is selected, and 10% of serum and 1% of double antibody are added in the preparation of the medium. Selecting cell culture bottle for culturing, adding 5-6mL culture medium into each bottle, and subculturing once every 2-3 days. When the cells grow to 80% -90% of the bottom surface of the culture flask, 0.25% of pancreatin is used for digestion, the cells are uniformly blown, and the cells are diluted to 10% ⁶ one/mL. Then, the cell suspension was transferred to a 60mm petri dish, 3mL of the cell suspension was added to each dish, mixed well, and then allowed to stand. After the cells are completely submerged, the cells are placed at 37 ℃ and 5% CO ₂ Culturing in an incubator for 24h, and adding medicine.

The experimental group was set up: the total number of the samples was 11, which were blank control group, model group, control group, model + example 1 group, model + example 2 group, model + example 3 group, model + example 4 group, model + example 5 group, model + example 6 group, model + example 7 group and model + example 8 group. Wherein, the HaCaT cells of the blank control group grow normally, and other substances are not added into the culture medium in the dosing process; the HaCaT cells in the model group are induced by LPS, and other substances are not added into a culture medium in the dosing process; inducing HaCaT cells of the control group by LPS, and adding a tea oil raw product into a culture medium in the dosing process; model + HaCaT cells of group 1 were induced by LPS, and during the dosing, the cosmetic of example 1 (10. Mu.g/mL) was added to the medium; model + HaCaT cells of group 2 were induced by LPS, and during the dosing, the cosmetic of example 2 (10. Mu.g/mL) was added to the medium; model + HaCaT cells of group 3 were induced by LPS, and the medium was supplemented with the cosmetic of example 3 (10. Mu.g/mL) during the dosing. The HaCaT cells of the model + example 4 group were induced by LPS, the cosmetic of example 4 (10 μ g/mL) was added to the medium during the drug addition, the HaCaT cells of the model + example 5 group were induced by LPS, the cosmetic of example 5 (10 μ g/mL) was added to the medium during the drug addition, the HaCaT cells of the model + example 6 group were induced by LPS, the cosmetic of example 6 (10 μ g/mL) was added to the medium during the drug addition, the cosmetic of example 7 (10 μ g/mL) was added to the medium during the drug addition, the HaCaT cells of the model + example 8 group were induced by LPS, and the cosmetic of example 8 (10 μ g/mL) was added to the medium during the drug addition.

And (3) detecting the ROS level: and taking out the 6-hole plate after adding the medicine for 24 hours, adding the DCFH-DA dye, and incubating for 30min. Then, the sample was taken out, washed 2 to 3 times with PBC at 4 ℃, observed under a fluorescence microscope, and photographed as shown in FIG. 4.

ROS level detection experiment, image J analysis was performed according to the results of the photography, and the results are shown in FIG. 5. The ROS level was significantly increased after LPS induction in the cells of the model group, whereas the fluorescence intensity was decreased more than that of the control group using the different examples. ROS level: model group > control group > model + example 3 group > model + example 6 group > model + example 4 group > model + example 1 group > model + example 5 group > model + example 7 group > model + example 2 group > model + example 8 group > blank control group. Experiments show that the tetrandrin can inhibit the oxidative stress generated after LPS induction.

Example 11 neutral Red phagocytic Capacity assay

The specific process is as follows:

THP-1 cells (purchased from the Chinese cell resource pool) were selected. RPMI-1640 culture medium is selected, and 10% of serum and 1% of double antibody are added in the preparation of the culture medium. Selecting cell culture bottle for culture, adding 5-6mL culture medium into each bottlePassaging every 2-3 days. When the cells grow to the logarithmic phase, the cells are uniformly blown and diluted to 10 ⁶ one/mL. Then transferring the cell suspension to a 6-pore plate, adding 2mL of cell suspension into each pore, adding PMA for induction, uniformly mixing, and standing. After the cells are completely submerged, the cells are placed at 37 ℃ and 5% CO ₂ Culturing in an incubator for 24h, and adding medicine.

The experimental group was set up: the total number of the groups was 11, which were blank control group, model group, control group, model + example 1 group, model + example 2 group, model + example 3 group, model + example 4 group, model + example 5 group, model + example 6 group, model + example 7 group and model + example 8 group. Wherein, the THP-1 cells of the blank control group grow normally, and other substances are not added into the culture medium in the drug adding process; THP-1 cells in the model group are induced by LPS, and other substances are not added into a culture medium in the dosing process; inducing THP-1 cells of the control group by LPS, and adding tea oil crude product into the culture medium in the drug adding process; model + THP-1 cells of the group of example 1 were induced by LPS, and the cosmetic of example 1 (10. Mu.g/mL) was added to the medium during the addition of the drug; model + THP-1 cells from group 2 were induced by LPS, and during the dosing, the cosmetic of example 2 (10. Mu.g/mL) was added to the medium; model + THP-1 cells from group 3 were induced by LPS, and the medium was supplemented with the cosmetic of example 3 (10. Mu.g/mL) during the dosing. Model + THP-1 cells of example 4 were induced by LPS, the cosmetic of example 4 (10. Mu.g/mL) was added to the medium during the drug addition, the THP-1 cells of model + example 5 were induced by LPS, the cosmetic of example 5 (10. Mu.g/mL) was added to the medium during the drug addition, the THP-1 cells of model + example 6 were induced by LPS, the cosmetic of example 6 (10. Mu.g/mL) was added to the medium during the drug addition, the THP-1 cells of model + example 7 were induced by LPS, the cosmetic of example 7 (10. Mu.g/mL) was added to the medium during the drug addition, the THP-1 cells of model + example 8 were induced by LPS, and the cosmetic of example 8 (10. Mu.g/mL) was added to the medium during the drug addition.

Neutral red phagocytosis: the old medium was removed and 100. Mu.L of neutral red solution was added and incubated for 2-3h. After completion, the medium was removed and washed 1 time with PBC at 4 ℃. Then 100. Mu.L of cell lysate was added and detected by microplate reader, OD _540nm . The samples for observation by the fluorescence microscope should be washed with PBS and then placedDirectly taking a picture under a microscope for observation.

The ability of the cells to phagocytose neutral red is detected, and the results of micrographs and enzyme-linked immunosorbent assay are shown in FIGS. 6 and 7. Phagocytic function is one of the major functions of macrophages, and its phagocytic activity can be evaluated by observing and detecting the amount of neutral red phagocytosis by cells. Using various examples, the ability of cells to phagocytose neutral red, as detected by the microplate reader, was significantly lower than that of the control group, and higher than that of the model group, with the values of the model group + example 8 being most similar to those of the control group. Meanwhile, according to the photographed results, a significant decrease in the amount of neutral red phagocytosed by individual cells in the model group was observed under a microscope. With the addition of the substances of the different examples, the amount of neutral red phagocytosed by the individual cells is obviously increased. Neutral red phagocytic capacity: blank control > model + example 8 > model + example 2 > model + example 7 > model + example 5 > model + example 4 > model + example 1 > model + example 6 > model + example 3 > control > model group. Experiments show that the tetrandrin can effectively inhibit the decrease of phagocytic capacity of cells induced by LPS.

The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.

Claims

1. A JAK1 signal pathway inhibitor is characterized in that the JAK1 signal pathway inhibitor is selected from tetrandrine, and the tetrandrine is one or more of tetrandrine and fangchinoline.

2. The JAK1 signaling pathway inhibitor according to claim 1, wherein the JAK1 signaling pathway inhibitor is used to inhibit expression of JAK1, STAT6mRNA and the associated cytokine IL-4 mRNA.

3. Use of a JAK1 signaling pathway inhibitor according to claim 1 or 2 in an anti-inflammatory soothing cosmetic.

4. The use of claim 3, wherein the anti-inflammatory soothing cosmetic comprises a cosmetic base and tetrandrine, wherein the tetrandrine is one or more of tetrandrine or tetrandrine.

5. The use as claimed in claim 4, wherein the content of tetrandrine is 0.1-2% by weight.

6. The use of claim 4 or 5, wherein the tetrandrine is composed of tetrandrine and fangchinoline, and the amount of tetrandrine is 40-100% of the total weight of the tetrandrine.

7. The use of claim 6, wherein the tetrandrine is added in an amount of 50-100% of the total weight of the tetrandrine.

8. The use of claim 4, wherein the purity of tetrandrine and fangchinoline is not less than 95%.

9. An anti-inflammatory soothing cosmetic comprising the JAK1 signaling pathway inhibitor of any one of claims 3 to 8.

10. A method of evaluating the anti-inflammatory activity of a JAK1 signaling pathway inhibitor in an anti-inflammatory, soothing cosmetic of claim 9, wherein the method is selected from the group consisting of:

the method 3 comprises the following steps: establishing a THP-1 cell model, and detecting the phagocytosis capacity of neutral red blood by means of photomicrography and OD value so as to evaluate the capacity of the anti-inflammatory and soothing cosmetics for relieving inflammatory reaction; method 1 or method 1 and method 2 and/or method 3.